All Blog Posts Tagged 'ErbB3' (2)

First Patients with Non-Small Cell Lung Cancer Dosed in Phase II Study of MM-121 in Combination with Erlotinib

The first patients, enrolled at the Loma Linda University Cancer Center, have been dosed in a Phase II clinical trial of MM-121 (also known as SAR256212), a drug candidate that targets ErbB3, a cell surface receptor, or protein attached to the cell membrane that mediates communication inside and outside the…

Continue

Added by Peter Hofland, PhD on November 18, 2011 at 1:30am — No Comments

Merrimack and Sanofi-aventis Enter Into an Exclusive Global Collaboration and Licensing Agreement for a Monoclonal Antibody in Oncology

French pharmaceutical company Sanofi-aventis (Paris, France) and Merrimack Pharmaceuticals Inc., a privately-held biotechnology company based in Cambridge, Massachusetts focusing on the discovery and development of novel treatments for cancer and autoimmune diseases, have entered in an exclusive global collaboration and licensing agreement on MM-121, a first-in-class,… Continue

Added by Peter Hofland, PhD on October 1, 2009 at 8:00pm — No Comments